A Phase 1 Study of MKC-1 in Patients With Refractory Hematologic Malignancies
Status:
Completed
Trial end date:
2009-04-01
Target enrollment:
Participant gender:
Summary
The main objectives of this study are to evaluate the side effects of MKC-1 and to determine
a safe dose of MKC-1 for future studies in patients with hematological malignancies